대학원

사경하 교수

사경하 교수

사경하 / Jason Kyungha Sa

  • 소속대학원 의학과
  • 직위조교수
  • 세부전공의과학 빅데이터
  • 연구실위치
  • 구내전화번호
  • 팩스
  • 이메일jasonksa@korea.ac.kr
학력사항
2005.09 -2009.06 University of California Santa Barbara, B.S.
2011.09- 2013.08 성균관대학교 삼성융합의과학원, M.S.
2013.09- 2017.02 성균관대학교 삼성융합의과학원, Ph.D
교육 및 경력사항
2009.11 -2011.08 Colorado Medical Pharmacy / Pharmacy Technician
2017.01 - 2019.08 삼성서울병원 / 선임연구원
2019.09 - 현재 고려대학교 의과대학 대학원 / 조교수
대표논문
● Shini H*, Sa JK*, Bae JS, Koo H, Jin S, Cho HJ, Choi SW, Kyoung JM, Kim JY, Seo YJ, Joung JG, Kim NKD, Son DS, Chung J, Lee T, Kong DS, Choi JW, Seol HJ, Lee JI, Suh YL, Park WY, Nam DH (2019) Clinical targeted next-generation sequencing panels for detection of somatic variants in gliomas, Cancer Research and Treatment, Epub ahead of print
● Zhang J, Caruso FP, Sa JK, Justesen S, Nam DH, Sims P, Ceccarelli M, Lasorella A, Iavarone A (2019) The combination of neoantigen quality and T lymphocyte infiltrates identifies glioblastoms with the longest survival, Communications Biology, 2:135
● Shin YJ*, Sa JK*, Lee Y, Kim D, Chang N, Cho HJ, Son M, Oh MYT, Shin K, Lee JK, Park J, Jo YK, Kim M, Paddison PJ, Tergaonkar V, Lee J, Nam DH (2019) PIP4K2A as a negative regulator of PI3K in PTEN-deficient glioblastoma, Journal of Experimental Medicine, 216(5):1120-1134
● Jeon HY, Ham SW, Kim JK, Jin X, Lee SY, Shin YJ, Choi CY, Sa JK, Kim SH, Chun T, Jin X, Nam DH, Kim H (2019) Ly6G+ inflammatory cells enable the conversion of cancer cells to cancer stem cells in an irrdiated glioblastoma model, Cell Death and Differentiation, Epub ahead of print
● Sa JK*, Choi SW*, Zhao J, Lee Y, Zhang J, Kong DS, Choi JW, Seol HJ, Lee JI, Iavarone A, Rabadan R, Nam DH (2019) Hypermutagenesis in untreated adult gliomas due to inherited mismatch mutations, International Journal of Cancer, 144(12):3023-3030
● Hu H, Mu Q, Bao Z, Chen Y, Liu Y, Chen J, Wang K, Wang Z, Nam Y, Jiang B, Sa JK, Cho HJ, Her NG, Zhang C, Zhao Z, Zhang Y, Zeng F, Wu F, Kang X, Liu Y, Qian Z, Wang Z, Huang R, Wang Q, Zhang W, Qiu X, Li W, Nam DH, Fan X, Wang J, Jiang T (2018) Mutational landscape of secondary glioblatoma guides MET-targeted trial in brain tumor, Cell, 175(6):1665-1678
● Lee JK*, Liu Z*, Sa JK*, Shin S*, Wang J*, Bordyuh M, Cho HJ, Elliott O, Chu T, Choi SW, Rosenbloom DS, Lee IH, Shin YJ, Kang HJ, Kim D, Kim SY, Sim MH, Kim J, Lee T, Seo YJ, Shin H, Lee M, Kim SH, Kwon YJ, Oh JW, Song M, Kim M, Kong DS, Choi JW, Seol HJ, Lee JI, Kim ST, Park JO, Kim KM, Song SY, Lee JW, Kim HC, Lee JE, Choi MG, Seo SW, Shim YM, Zo JI, Jeong BC, Yoon Y, Ryu GH, Kim NKD, Bae JS, Park WY, Lee J, Verhaak RGW, Iavarone A, Lee J, Rabadan R, Nam DH (2018) Pharmacogenomic landscape of patient-derived tumor cells informs precision oncology therapy, Nature Genetics, 50(10):1399-1411
● Barnes JM, Kaushik S, Bainer RO, Sa JK, Woods EC, Kai FB, Przybyla P, Lee M, Lee HW, Tung JC, Maller O, Barrett AS, Lu KV, Lakins JN, Hansen KC, Obernier K, Alvarez-Buylla A, Bergers G, Phillips JJ, Nam DH, Bertozzi CR, Weaver VM (2018) A tension-mediated glycocalyx-integrin feedback loops promotes a mesenchymal-like phenotype in glioblastoma that promotes tumor growth, invasion and drug resistance, Nature Cell Biology, 20(10):1203-1214
● Cho HJ, Zhao J, Jung SW, Ladewig E, Kong DS, Suh YL, Lee Y, Kim D, Ahn SH, Bordyuh M, Kang HJ, Sa JK, Seo YJ, Kim ST, Lim DH, Dho YS, Lee JI, Seol HJ, Choi JW, Park WY, Park CK, Rabadan R, Nam DH (2018) Distinct genomic profile and specific targeted drug responses in adult cerebellar glioblastoma, Neuro-Oncology, 21(1):47-58
● Sa JK*, Kim SH*, Lee JK, Cho HJ, Shin YJ, Shin H, Koo H, Kim D, Lee M, Kang W, Hong SH, Kim JY, Park YW, Song SW, Lee SJ, Joo KM, Nam DH (2018) Identification of genomic and molecular traits that present therapeutic vulnerability to HGF-targeted therapy in glioblastoma, Neuro-Oncology, 21(2):222-233
● Lee J, Kim D, Son E, Yoo SJ, Sa JK, Shin YJ, Yoon Y, Nam DH (2018) Pharmacokinetics, biodistribution, and toxicity evaluation of anti-SEMA3A (F11) in in vivo models, Anticancer Research, 38(5):2803-2810
● Sim J, Nam DH, Kim Y, Lee IH, Choi JW, Sa JK, Suh YL (2018) Comparison of 1p and 19q status of glioblastoma by whole exome sequencing, array-comparative genomic hybridization, and fluorescence in situ hybridization, Medical Oncology, 35(5):60
● Choi SW, Shin H, Sa JK, Cho HJ, Koo H, Kong DS, Seol HJ, Nam DH (2018) Identification of transcriptome signature for predicting clinical response to bevacizumab in recurrent glioblastoma, Cancer Medicine, 7(5):1774-1783
● GLASS Consortium (2018) Glioma through the looking GLASS: molecular evolution of diffuse gliomas and the glioma longitudinal analysis consortium, Neuro-Oncology, 20(7):873-884
● Lee J, Shin YJ, Lee K, Cho HJ, Sa JK, Lee SY, Kim SH, Lee J, Yoon Y, Nam DH (2018) Anti-SEMA3A antibody: a novel therapeutic agent to suppress glioblastoma tumor growth, Cancer Research and Treatment, 50(3):1009-1022
● Park H, Kim D, Son E, Shin S, Sa JK, Kim SH, Yoon Y, Nam DH (2017) Antitumor activity, pharmacokinetics, tumor-homing effect, and hepatotoxicity of a species cross-reactive c-Met antibody, Biochemical and Biophysical Research Communications, 494(1-2):409-415
● Park H, Kim D, Kim E, Sa JK, Lee HW, Yu S, Oh J, Kim SH, Yoon Y, Nam DH (2017) Tumor inhibitory effect of IRCR201, a novel cross-reactive c-Met antibody targeting the PSI domain, International Journal of Molecular Sciences, 18(9). pii: E1968
● Yin J, Oh YT, Kim JY, Kim SS, Choi E, Kim TH, Hong JH, Chang N, Cho HJ, Sa JK, Kim JC, Kwon HJ, Park S, Lin W, Nakano I, Gwak HS, Yoo H, Lee SH, Lee J, Kim JH, Kim SY, Nam DH, Park MJ, Park JB (2017) Transglutaminase 2 inhibition reverses mesenchymal transdifferentiation of glioma stem cells by regulating C/EBPβ signaling, Cancer Research, 77(18):4973-4984
● Lee JK*, Wang J*, Sa JK*, Ladewig E*, Lee HO, Lee IH, Kang HJ, Rosenbloom DS, Camara PG, Liu Z, Nieuwenhuizen PV, Jung SW, Choi SW, Kim JH, Chen A, Kim KT, Shin S, Seo YJ, Oh JM, Shin YJ, Park CK, Kong DS, Seol HJ, Blumberg A, Lee JI, Iavarone A, Park WY, Rabadan R, Nam DH (2017) Spatiotemporal genomic architecture informs precision oncology in glioblastoma, Nature Genetics, 49(4):594-599
● Sa JK, Lee IH, Hong SD, Kong DS, Nam DH (2016) Genomic and transcriptomic characterization of skull base chordoma, Oncotarget, 8(1):1321-1328
● Kim DG, Kim KH, Seo YJ, Yang H, Marcusson EG, Son E, Lee K, Sa JK, Lee HW, Nam DH (2016) Anti-miR delivery strategies to bypass the blood-brain barrier in glioblastoma therapy, Oncotarget, 7(20):29400-11
● Cho YJ, Kang W, Kim SH, Sa JK, Kim N, Paddison PJ, Kim M, Joo KM, Hwang YI, Nam DH (2016) Involvement of DDX6 gene in radio- and chemoresistance in glioblastoma, International Journal of Oncology, 48(3):1053-62
● Sa JK*, Yoon Y*, Kim M*, Kim Y*, Cho HJ, Lee JK, Kim GS, Han S, Kim WJ, Shin YJ, Joo KM, Paddison PJ, Ishitani T, Lee J, Nam DH (2015) In vivo RNAi screen identifies NLK as a negative regulator of mesenchymal activity in glioblastoma, Oncotarget, 6(24):20145-59

목록